| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.82 B USD | 8.67 B USD | 8.41 B USD | 9.15 B USD | 9.31 B USD | 8.29 B USD | 4.97 B USD | 4.54 B USD | 4.00 B USD | 3.16 B USD | 2.82 B USD | 2.62 B USD |
| Depreciation & Amortization | 1.05 B USD | 1.16 B USD | 1.07 B USD | 986.00 M USD | 831.00 M USD | 658.00 M USD | 564.00 M USD | 2.27 B USD | 2.03 B USD | 1.76 B USD | 1.69 B USD | 1.68 B USD |
| Stock-Based Compensation | 310.00 M USD | 301.00 M USD | 278.00 M USD | 307.00 M USD | 230.00 M USD | 196.00 M USD | 181.00 M USD | 181.00 M USD | 159.00 M USD | 133.50 M USD | 125.00 M USD | 117.10 M USD |
| Capital Expenditures | 1.52 B USD | 1.40 B USD | 1.48 B USD | 2.24 B USD | 2.52 B USD | 1.47 B USD | 926.00 M USD | 758.00 M USD | 508.00 M USD | 444.40 M USD | 422.90 M USD | 427.60 M USD |
| Cash Flow from Investing | -4.05 B USD | -5.84 B USD | -5.14 B USD | -2.16 B USD | -21.93 B USD | -1.51 B USD | -1.49 B USD | -1.25 B USD | -7.73 B USD | -5.52 B USD | -1.09 B USD | -11.78 B USD |
| Cash Flow from Financing | 1.80 B USD | -6.79 B USD | -3.62 B USD | -2.81 B USD | 6.58 B USD | 959.00 M USD | -3.12 B USD | -2.24 B USD | 3.85 B USD | 2.76 B USD | -2.62 B USD | 4.80 B USD |
| Dividends Paid | 636.00 M USD | 583.00 M USD | 523.00 M USD | 455.00 M USD | 395.00 M USD | 337.00 M USD | 297.00 M USD | 266.00 M USD | 237.00 M USD | 238.40 M USD | 240.60 M USD | 234.80 M USD |
| Stock Buybacks | 3.00 B USD | 4.00 B USD | 3.00 B USD | 3.00 B USD | 2.00 B USD | 1.50 B USD | 1.50 B USD | 500.00 M USD | 750.00 M USD | 1.25 B USD | 500.00 M USD | 0 USD |
| Free Cash Flow | 6.29 B USD | 7.27 B USD | 6.93 B USD | 6.91 B USD | 6.79 B USD | 6.82 B USD | 4.05 B USD | 3.79 B USD | 3.50 B USD | 2.71 B USD | 2.39 B USD | 2.19 B USD |
Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company operates through four main segments: analytical technologies, which focuses on advanced instrumentation for research and analysis; specialty diagnostic products for clinical and healthcare applications; life science solutions offering reagents and tools for biological research; and lab products and services, including contract research organization services to support scientific workflows. These offerings enable advancements in healthcare, pharmaceuticals, biotechnology, and academic research by delivering high-quality tools for discovery, development, and production processes. Thermo Fisher Scientific Inc. serves a global customer base across research institutions, pharmaceutical companies, diagnostics providers, and industrial sectors, facilitating innovation in drug development, genomics, proteomics, and clinical diagnostics. Founded in 2006 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. plays a pivotal role in enabling scientific breakthroughs and operational efficiency in life sciences and healthcare markets.